Overview
The acute vulvovaginal candidiasis market involves the development of various medications and drugs for treatment of this infection. Acute vulvovaginal candidiasis (VVC) or vaginal thrush is a yeast infection which is caused by group of fungus called as candida albicans. The infection is caused by over-growth of fungus which leads to symptoms such as abnormal vaginal discharge, severe pain while intercourse, and vaginal itching. Around 75% of women are estimated to experience the VVC in their lifetime. Most of the VVC cases are mild but some the infection gets severe in some women which causes swelling, cracks on the wall of vagina and redness.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/4315
Drivers
Accelerated research and development on drugs and treatments of VVC is expected to propel growth of the global acute vulvovaginal candidiasis market during the forecast period. In April 2020, Scynexis Inc., revealed the promising results of Phase III trials which were conducted to check the effectiveness of an anti-fungal drug, ibrexafungerp for treating VVCs.
Close race among the market players to submit the new drug application (NDA) to the regulatory bodies which will grant them the approval for manufacturing their drugs. This factor is expected to propel the growth of global acute vulvovaginal candidiasis market.
Restraints
The prevalence of COVID-19 epidemic is expected to restrain growth of the global acute vulvovaginal candidiasis market during the forecast period.
Opportunities
Increasing patients of vaginal yeast infections is expected to pave the way of opportunities for growth of global acute vulvovaginal candidiasis market over the forecast period.
Regional Insights
Asia Pacific is expected to witness a significant growth during the forecast period of global acute vulvovaginal candidiasis market. Rising awareness regarding this infection among the rural women and the initiatives such as ‘Swachhta, Swasthya and Suvidha’ taken by the Indian government for the hygiene of underprivileged women, are the driving factors for the growth of global acute vulvovaginal candidiasis market in this region.
North America is expected to experience a robust growth over the forecast period of global acute vulvovaginal candidiasis market.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4315
Competitive Section
Key players operating in the global acute vulvovaginal candidiasis market are S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, Inc., ., Scynexis, Inc., IncBasilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, and Mycovia Pharmaceuticals.
Key Takeaways
In October 2019, the American pharmaceutical company, Mycovia Pharmaceuticals announced its collaboration with the Hungarian pharmaceutical company, Gedeon Richter to manufacture VT-1161 for treatment of vulvovaginal candidiasis.
In February 2021, the bio-tech company, Scynexis announced its agreement with the pharmaceutical company, Amplity Health to extend their support for the U.S. commercialization of BrexafemmeTM which is a brand name of Ibrexafungerp for vaginal infections.
Reasons to Purchase this Report
• Current and future of global Acute Vulvovaginal Candidiasis Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Key Developments
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Market Share Analysis
- Brand Analysis
- Market Dynamics
- Acute Vulvovaginal Candidiasis Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
- During COVID-19 Market Situation
- Supply Side and Demand Side Analysis
- Impact of COVID-19 on Acute Vulvovaginal Candidiasis Treatment Market
- Government Initiatives to Combat COVID-19
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Drug Type, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Clotrimazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Nystatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Ketoconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Terbinafine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Terconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Acute Vulvovaginal Candidiasis Treatment Market, By Region, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Mycovia Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Scynexis, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Grupo Ferrer Internacional, S.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pacgen Life Science Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- NovaDigm Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Cidara Therapeutics, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Amplyx Pharmaceuticals Inc.,
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Mycovia Pharmaceuticals, Inc.
- Analyst Views
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837